• Início
  • Resultados da busca
  • Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance.

Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance.

The Journal of antimicrobial chemotherapy (2014-08-26)
Rossarin Suwanarusk, Bruce Russell, Alice Ong, Kanlaya Sriprawat, Cindy S Chu, Aung PyaePhyo, Benoit Malleret, François Nosten, Laurent Renia
RESUMO

Methylene blue, once discarded due to its unsettling yet mild side effects, has now found a renewed place in the pharmacopoeia of modern medicine. The continued spread of drug-resistant Plasmodium vivax and Plasmodium falciparum has also led to a recent re-examination of methylene blue's potent antimalarial properties. Here we examine the ex vivo susceptibility profile of Plasmodium spp. isolates to methylene blue; the isolates were from a region on the Thai-Myanmar border where there are increasing rates of failure when treating vivax malaria with chloroquine. To do this we used a newly developed ex vivo susceptibility assay utilizing flow cytometry and a portable flow cytometer with a near-UV laser. P. vivax (median methylene blue IC50 3.1 nM, IQR 1.7-4.3 nM) and P. falciparum (median methylene blue IC50 1.8 nM, IQR 1.6-2.3 nM) are susceptible to methylene blue treatment at physiologically relevant levels. Unfortunately, the addition of chloroquine to combination treatments with methylene blue significantly reduces the ex vivo effectiveness of this molecule. Our data support further efforts to employ methylene blue as a safe, low-cost antimalarial to treat drug-resistant malaria.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Dihydroethidium, ≥95%
Sigma-Aldrich
Dihydroethidium, BioReagent, suitable for fluorescence, ≥95% (HPCE)

Redes sociais

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Pesquisa. Desenvolvimento. Produção.

Somos um fornecedor global líder para o setor de ciências biológicas, com soluções e serviços para pesquisa, desenvolvimento e produção de biotecnologia, além de produção e desenvolvimento de terapias farmacológicas com medicamentos.

© 2021 Merck KGaA, Darmstadt, Alemanha e/ou suas filiais. Todos os direitos reservados.

A reprodução não autorizada de quaisquer materiais deste site é estritamente proibida.